Market Overview:
The global antibodies in oncology market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth of this market is mainly attributed to the increasing prevalence of cancer, rising demand for targeted therapies, and technological advancements in the field of antibody-based therapeutics. The global antibodies in oncology market can be segmented by type, application, and region. By type, the market can be divided into murine antibodies, chimeric and humanized antibodies, fully humanized antibodies, and others. By application, the market can be classified into hospitals, academic institutes,, clinics,.and others). Geographically speaking,,the global antibodies in oncologymarket is segmented into North America,, Latin America,, Europe,,,, Asia Pacific,,,,and Middle East & Africa (MEA). Of these regions,.North America currently dominates the global Antibodies In Oncology Market due to factors such as early adoption of novel technologies,.high per capita healthcare expenditure,.and well-established reimbursement scenario for antibody-based therapies. However.
Product Definition:
An antibody is a protein produced by the body's immune system in response to a foreign substance, such as a virus or bacteria. In oncology, antibodies are used to detect and target cancer cells for destruction.
Murine Antibodies:
The human body normally produces antibodies to fight off infections and diseases. Sometimes, the immune system malfunctions and the body cannot produce normal antibodies. In such cases, an antibody-based drug or biologic therapy can be used to treat the patient. Antibody therapeutics are among one of the most important areas in oncology and immunology research today due to their potential use in treating a wide variety of cancers as well as autoimmune diseases (such as rheumatoid arthritis).
Chimeric and Humanised Antibodies:
Antibodies in cancer diagnostics and therapeutics have been a major focus area for research over the past decade. The use of monoclonal antibodies has increased significantly due to their ability to target specific antigens on the cell surface. This allows them to act as an effective immune response against various cancers, thereby resulting in tumor destruction.
Application Insights:
On the basis of application, the global antibodies in oncology market is segmented into hospitals, academic institutes and clinics. Hospitals held the largest share in 2017 owing to availability of a large patient base for cancer treatment coupled with presence of world class researchers and clinicians. The hospital segment is anticipated to maintain its dominance throughout the forecast period due to factors such as increasing number of cancer patients globally coupled with rising awareness about various types of antineoplastic drugs.
The clinic segment is expected to witness lucrative growth over next few years due largely unmet medical needs for targeted therapy against resistant tumor cells which are driving demand for highly specific therapeutic proteins that can overcome these challenges. Increasing adoption rate and effectiveness among patients across different regions are further boosting revenue generation from this sector at a rapid pace.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of biotechnology and pharmaceutical companies, which are engaged in cancer research. Moreover, these players are also involved in drug development for other diseases using their expertise gained from working on cancer therapies. Thus, this results in an increased availability of fully humanized antibodies as well as chimeric and humanized antibodies for use against various cancers such as bladder, breast, lung & bronchial carcinoma and others.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as increasing prevalence of cancer among immunocompromised patients due to HIV or exposure to radiation; rising awareness about early diagnosis; growing investments by major players for expansion; collaborations between academic institutes and industry players that focus on R&D pertaining specifically towards anti-cancer therapies.; etc.). These aforementioned factors have resulted into high demand within Asia Pacific region thus far during the forecast period (2017).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the antibodies in oncology market. According to the American Cancer Society, around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and approximately 600,920 people will die from the disease. This number is expected to rise significantly over the next few years due to population growth and aging.
- Rising demand for targeted therapies: The growing demand for targeted therapies is another key factor driving market growth. Antibodies are increasingly being used as therapeutic agents due to their ability to specifically target tumor cells without affecting normal cells. This has led to a significant increase in their use in both early-stage and advanced cancers patients across all major markets worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Antibodies in Oncology Market Research Report
By Type
Murine Antibodies, Chimeric and Humanised Antibodies, Fully Humanized Antibodies, Others
By Application
Hospitals, Academic Institutes, Clinics
By Companies
Novartis International AG, GlaxoSmithKline plc, Biogen Idec Inc., Bristol Myers Squibb Co., AstraZeneca plc., Celltrion, 3SBIO, Celgen Biopharma, Dr Reddy’s
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
123
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Antibodies in Oncology Market Report Segments:
The global Antibodies in Oncology market is segmented on the basis of:
Types
Murine Antibodies, Chimeric and Humanised Antibodies, Fully Humanized Antibodies, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Academic Institutes, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis International AG
- GlaxoSmithKline plc
- Biogen Idec Inc.
- Bristol Myers Squibb Co.
- AstraZeneca plc.
- Celltrion
- 3SBIO
- Celgen Biopharma
- Dr Reddy’s
Highlights of The Antibodies in Oncology Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Murine Antibodies
- Chimeric and Humanised Antibodies
- Fully Humanized Antibodies
- Others
- By Application:
- Hospitals
- Academic Institutes
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antibodies in Oncology Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antibodies are proteins that help the body fight against infection. They are also used in oncology to help identify and treat cancer cells.
Some of the major companies in the antibodies in oncology market are Novartis International AG, GlaxoSmithKline plc, Biogen Idec Inc., Bristol Myers Squibb Co., AstraZeneca plc., Celltrion, 3SBIO, Celgen Biopharma, Dr Reddy’s.
The antibodies in oncology market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antibodies in Oncology Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antibodies in Oncology Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antibodies in Oncology Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antibodies in Oncology Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antibodies in Oncology Market Size & Forecast, 2018-2028
4.5.1 Antibodies in Oncology Market Size and Y-o-Y Growth
4.5.2 Antibodies in Oncology Market Absolute $ Opportunity
Chapter 5 Global Antibodies in Oncology Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antibodies in Oncology Market Size Forecast by Type
5.2.1 Murine Antibodies
5.2.2 Chimeric and Humanised Antibodies
5.2.3 Fully Humanized Antibodies
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antibodies in Oncology Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antibodies in Oncology Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Academic Institutes
6.2.3 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antibodies in Oncology Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antibodies in Oncology Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antibodies in Oncology Analysis and Forecast
9.1 Introduction
9.2 North America Antibodies in Oncology Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antibodies in Oncology Market Size Forecast by Type
9.6.1 Murine Antibodies
9.6.2 Chimeric and Humanised Antibodies
9.6.3 Fully Humanized Antibodies
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antibodies in Oncology Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Academic Institutes
9.10.3 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antibodies in Oncology Analysis and Forecast
10.1 Introduction
10.2 Europe Antibodies in Oncology Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antibodies in Oncology Market Size Forecast by Type
10.6.1 Murine Antibodies
10.6.2 Chimeric and Humanised Antibodies
10.6.3 Fully Humanized Antibodies
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antibodies in Oncology Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Academic Institutes
10.10.3 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antibodies in Oncology Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antibodies in Oncology Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antibodies in Oncology Market Size Forecast by Type
11.6.1 Murine Antibodies
11.6.2 Chimeric and Humanised Antibodies
11.6.3 Fully Humanized Antibodies
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antibodies in Oncology Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Academic Institutes
11.10.3 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antibodies in Oncology Analysis and Forecast
12.1 Introduction
12.2 Latin America Antibodies in Oncology Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antibodies in Oncology Market Size Forecast by Type
12.6.1 Murine Antibodies
12.6.2 Chimeric and Humanised Antibodies
12.6.3 Fully Humanized Antibodies
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antibodies in Oncology Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Academic Institutes
12.10.3 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antibodies in Oncology Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antibodies in Oncology Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antibodies in Oncology Market Size Forecast by Type
13.6.1 Murine Antibodies
13.6.2 Chimeric and Humanised Antibodies
13.6.3 Fully Humanized Antibodies
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antibodies in Oncology Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Academic Institutes
13.10.3 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antibodies in Oncology Market: Competitive Dashboard
14.2 Global Antibodies in Oncology Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis International AG
14.3.2 GlaxoSmithKline plc
14.3.3 Biogen Idec Inc.
14.3.4 Bristol Myers Squibb Co.
14.3.5 AstraZeneca plc.
14.3.6 Celltrion
14.3.7 3SBIO
14.3.8 Celgen Biopharma
14.3.9 Dr Reddy’s
